Clinical Trial for Bipolar Disorder, now recruiting

[HysteryDiagnosis]

http://www.clinicaltrials.gov/ct2/show/NCT00327756?term=parkinson%27s+coenzyme+q10&rank=6

Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder

Sponsored by: National Institute of Mental Health (NIMH)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00327756

Purpose

This study will examine whether mitochondrial function is impaired in patients with bipolar disorder. Mitrochondria are small organelles inside the cell that are responsible for energy production. Recent studies in animals and humans suggest that abnormalities of mitrochondria may be involved in bipolar depression. The study will also examine whether the food supplement Coenzyme Q10 (CoQ10) improves mitochondrial function and symptoms such as depressed mood, low energy, anxiety or slowness in thinking and movements in bipolar patients. CoQ10 has been used to increase cell energy production and as an antioxidant. It has had some benefit in patients with Parkinson's disease and migraine and in prolonging survival in patients with cancer and heart failure.

Patients 18-65 years of age with bipolar disorder who are currently in a depressive episode of at least 4 weeks duration may be eligible for this study. The study has four phases, as follows:

Phase I: Medication Withdrawal

Patients taper off all psychotropic medications, usually over 1 to 2 weeks.

Phase II: Baseline Evaluation

After being off all medication for about 2 weeks, patients undergo the following procedures:

* Magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). The two procedures are performed in an MRI scanner. Both tests use a strong magnetic field and radio waves to obtain images that provide information on brain anatomy and chemistry.
* Blood tests to assess mitochondrial function isolated from blood cells.
* Skin biopsy for tests of mitochondria. A small sample of skin tissue 5 x 5 millimeters is surgically removed.

Phase III: Administration of CoQ10 or Placebo

Participants are randomly assigned to take either CoQ10 or placebo (an inactive look-alike substance) twice a day by mouth. While taking the study medication, patients have the following procedures periodically:

* Rating scales for anxiety and depression and adverse events.
* Check of vital signs.
* Blood and urine sample collections.


Please follow first link for the rest of the details on this trial.



http://www.clinicaltrials.gov/ct2/results?term=parkinson%27s+coenzyme+q10
Others may want to look into the results or the possibility of enrolling in a few of the following trials:


1 Completed Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease
Condition: Parkinson's Disease
Interventions: Drug: Coenzyme Q10 Nanodispersion (Nanoquinone); Drug: Placebo

2 Completed Parkinson's Disease Treatment With Coenzyme Q10
Condition: Parkinson's Disease
Intervention: Drug: Coenzyme Q10

3 Completed NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485
Condition: Parkinson Disease
Interventions: Drug: CoQ10; Drug: GPI 1485

4 Recruiting Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)
Conditions: Progressive Supranuclear Palsy; Atypical Parkinsonism
Intervention: Drug: Coenzyme Q10

5 Recruiting Coenzyme Q10 in Huntington's Disease (HD)
Condition: Huntington's Disease
Interventions: Drug: coenzyme Q10; Other: placebo

6 Recruiting Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder
Conditions: Bipolar Affective Disorder; Depression
Intervention: Drug: Coenzyme Q10

7 Completed Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy
Condition: Progressive Supranuclear Palsy
Intervention: Drug: Coenzyme Q10